Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

Dsuvia: A Dull US FDA Review Preceded The Controversial Approval

Jul 16 2019

• By Michael Cipriano

Related Content

Opioid Sponsors Enter 2019 At A Crossroads

Dec 31 2018

Dsuvia Approval May Be Followed By New Opioid Review Paradigm At FDA

Nov 02 2018

Keeping Track: A CRL For Tlando, An Accelerated Approval For AndexXa, And A Burst Of Supplemental Approvals

May 12 2018

Public Citizen: US FDA Deliberately Excluded Risk Committee From Dsuvia Panel To Get Positive Vote

Oct 19 2018

AcelRx's Sublingual Opioid Dsuvia Brings Unique Risk To Advisory Panel: Dropped Tablets

Oct 11 2018

Dsuvia's Thumbs Up From US FDA Advisory Panel Is First Positive Vote For An Opioid In 2018

Oct 15 2018

New Opioids May Need Comparative Effectiveness Data For Approval

Jun 21 2019

Related Companies

Talphera, Inc.

Additional Topics

United States Regulation Drug Review Profile Neurology BioPharmaceutical

More from Drug Review Profiles

More from Product Reviews

Twitter feed RSS feed RSS feed

About UsOpens in new window
Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us
Customer Service
Subscribe
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window